2017_03_BioscienceSolutions _16-9_1920x995_px2.jpg
2013
YEAR
116

Lonza expanded their Antibody Drug Conjugate (ADC) manufacturing capacity in Visp, Switzerland to meet the growing customer demand. The expansion of the ADC facility will doubled the existing large-scale manufacturing capacity in Visp while allowed for current operations to continue without interruption.

ADC isolator in Visp, Switzerland
ADC isolator in Visp, Switzerland